Stocksigma LogoStocksigma Logo

Bajaj Healthcare Reports Strong Q2 FY27 Earnings Driven by Formulations Growth

Bajaj Healthcare posted an 18.9% YoY increase in Q2 FY27 revenue from operations to Rs. 175.9 Crore, with EBITDA rising 12.2% YoY to Rs

Bajaj Healthcare Reports Strong Q2 FY27 Earnings Driven by Formulations Growth

Bajaj Healthcare Ltd 路 Press Release 路 18 Oct 2026, 3:58 am

Bajaj Healthcare Reports Strong Q2 FY27 Earnings Driven by Formulations Growth Bajaj Healthcare posted an 18.9% YoY increase in Q2 FY27 revenue from operations to Rs. 175.9 Crore, with EBITDA rising 12.2% YoY to Rs. 32.1 Crore and PAT growing 26.9% YoY to Rs. 14.1 Crore. Formulations surged 82.0% YoY to Rs. 41.7 Crore, while API exports expanded 28.5% YoY to Rs. 62.6 Crore. The company secured first-in-India DCGI approval and commenced commercial rollout for Cenobamate Tablets in Sep'26. Additionally, India Ratings upgraded its long-term rating to IND A/Stable.

Original exchange filing (PDF)

More announcements from Bajaj Healthcare Ltd

All Bajaj Healthcare Ltd announcements